$ASBP

Biotech stocks rose as several companies issued updates. Wellgistics Health (WGRX) completed a rebrand to DataMEDS AI and will trade as MEDS; it reported Q1 2026 revenue of $0.929M and expects $1.775M in Q2. Dyadic (DYAI) saw a major shareholder sell. Palvella (PVLA) submitted the first NDA module for QTORIN. Sol-Gel (SLGL) expects SGT-610 Phase 3 data in Q4 2026.

Aspire Biopharma Holdings, Inc. (ASBP) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. false 0001847345 0001847345 2026-06-16 2026-06-16 0001847345 ASBP:CommonStockParValue0.0001PerShareMember 2026-06-16 2026-06-16 0001847345 ASBP:WarrantsEachExercisableForOneShareOfCommonStockMember 2026-06-16 2026-06-16 iso4217:USD xbrli:shares iso4217:USD xbrli:shares UNITED STA

Aspire Biopharma Holdings, Inc. (ASBP) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. EX-10.1 2 ex10-1.htm EX-10.1 Exhibit 10.1 PURCHASE AGREEMENT between FireFish TopCo, LLC and Aspire Biopharma Holdings, Inc. Dated as of June 10, 2026 TABLE OF CONTENTS Article I DEFINITIONS AND INTERPRETATIONS 1 Section 1.01. Definitions 1 Article II CLOSING 1 Section 2.01. Clos

Biotech stocks rose Monday as investors reacted to clinical and regulatory updates. Tango Therapeutics (TNGX) jumped 52.97% after initial Phase 1/2 pancreatic cancer data showed 90% 6-month PFS; Alvotech (ALVO) gained 19.77% as the FDA accepted its Entyvio interchangeable biosimilar AVT16; Zevra (ZVRA) rose 13.95% on an Orange Book listing for MIPLYFFA.

SciSparc (SPRC) shares rose ~140% after its TSX Venture subsidiary received conditional approval to buy ~54% of private Israeli CliniQuantum for 56.6M NeuroThera shares (~$9.46M). Co-Diagnostics (CODX) gained ~53% for a third day amid Ebola PCR assay progress. Akari (AKTX) jumped ~38% on ASCO abstract acceptance and new KRAS-mutant synergy data; Outlook (OTLK) rose ~26% ahead of a June FDA resubmission.

Aspire Biopharma (Nasdaq: ASBP) CEO Kraig Higginson sent a shareholder letter outlining plans for 2026. The board authorized a $5.0 million share repurchase after a preferred-stock private placement generated about $21.0 million net proceeds and the company regained Nasdaq equity compliance. Aspire said it plans to file an NDA for its high-dose sublingual aspirin via the 505(b)(2) pathway by end-2026. It also proposed acquiring Dura Driver Control Systems for $30 million cash; DCS reported 2025

Aspire Biopharma Holdings (ASBP) will implement a 1-for-30 reverse stock split on May 11, 2026. This action will consolidate shares, reduce the total share count, and assign a new CUSIP number while retaining the existing ticker symbol. The company, operating in the biopharmaceutical sector, aims to manage its market position through this capital markets action.

Aspire Biopharma Holdings, Inc. announced its Letter of Intent to acquire Dura Driver Control Systems (DCS), a leading global automotive supplier. The acquisition, valued at $30 million in cash, is expected to transform Aspire into a diversified, high-revenue enterprise, leveraging DCS's robust financial performance of over $200 million in revenue and $20 million in Adjusted EBITDA for FY2025. DCS specializes in automotive driver control systems with a strong patent portfolio and global manufacturing presence.

Aspire Biopharma (NASDAQ:ASBP), a biopharmaceutical company, has signed a Letter of Intent to acquire Dura Driver Control Systems (DCS), a global automotive supplier, for $30 million in cash. DCS reported over $200 million in revenue and $20 million in adjusted EBITDA for FY2025 (unaudited), marking a significant diversification for Aspire Biopharma from its biotech focus into the automotive industry. The acquisition is subject to due diligence and a U.S. GAAP audit, and if completed, will bolster DCS's management with experienced automotive leadership.

Aspire Biopharma has submitted a Pre-IND meeting request and briefing package to the U.S. FDA for its sublingual aspirin product designed to treat suspected acute myocardial infarction (AMI). This fast-acting, high-dose formulation has shown in clinical trials to inhibit platelet aggregation significantly faster than chewed aspirin, offering a potentially life-saving advantage. The company is pursuing a 505(b)(2) regulatory pathway, which could streamline the approval process by leveraging existing data on aspirin.